2012 Bioscience Company of the Year - Cord Blood Registry
The first cord blood sample ever saved by a family belonged to the son of CBR's Scientific Director. Two decades later, CBR (Cord Blood Registry) is the largest, most experienced stem cell bank, entrusted by families worldwide. Thanks to expecting families like yours, more than 400,000 children have newborn stem cells saved with CBR. As you decide what's best for your family, it's important to understand the CBR difference in quality and experience. CBR has banked more stem cells than any other family bank and has the most experience helping families use their cord blood for medical treatments. In October 2012, CBR was named the Arizona Bioscience Company of the Year.
Update from ASU Biodesign's Dr. Raymond DuBois
Dr. Ray DuBois , M.D., Ph.D. Dr. DuBois is a world-renowned physician-scientist who has devoted his career to understanding the linkages between inflammation and cancer, particularly colon cancer. He assumed his new role as Executive Director of the Biodesign Institute in December of 2012, coming by way of Houston as provost of the prestigious M.D. Anderson Cancer Center.
Lightworks Algae Energy ASU Research
The Arizona Center for Algae Technology and Innovation (AzCATI) at Arizona State University and the Algae Testbed Public-Private Partnership (ATP3) are working with Health Enhancement Products, Inc (HEPI) to advance the science behind algae-based health and wellness products like vitamins and food chemicals.
STEM: Nadja Anderson Interview Part 2
2011 Bioscience Educator of the Year, Dr. Nadja Anderson, director of the BIOTECH Project for University of Arizona’s BIO5 Institute, shows some the materials used to demonstrate DNA extraction at science festivals and during classroom visits. Read the article Biosciences Education >>
Championing Patient Safety: Ventana
Anatomic pathology labs today face critical shortages in technicians, along with increasing demands to produce better quality results, faster.While the average pathology lab maintains a 99% quality rate, that leaves a 1% margin for error that could mean as many as 6 misidentified samples every single week for an average size lab*. When real patient results are at risk, even a small margin of error is unacceptable. Now, more than ever, we must safeguard every patient...every step of the way.Here, you will learn about pathology lab process errors that compromise the integrity of patient results, and the solutions that can put your lab on a SaferPath.
From Bioscience to Biobusiness Success
Dr. Robert Bowser was recruited to the Barrow Neurological Institute and St. Joseph’s Hospital & Medical Center to direct an ALS research center using philanthropic support from Mr. Ira Fulton. He arrived to the Phoenix area in August of last year after 18 years on the faculty at the University of Pittsburgh School of Medicine. Dr. Bowser’s research focuses on biomarkers of neurologic disease and he will describe how success in his academic research has also led to success in the world of biotechnology.
Yulex moves into the AZBio Fast Lane
http://www.yulex.com/ Rubber and commerce go hand in hand and rubber products are everywhere. Yulex Corporation is the global leader in guayule-based biomaterials for a wide range of markets and diverse applications. Yulex’s Guayule BioRubber Emulsions and BioRubber Solids have medical, consumer, and industrial applications to grow an increasingly diverse market community with ultra-pure, high-performance products. From medical devices to fabric coatings, and from bedding to industrial packaging adhesives, Yulex also provides technical and product development guidance and support, and even custom material compounding and formulation. Yulex Corporation, a technology, marketing and biomaterial product development company that applies sustainable crop science, clean bioprocessing, and materials science for the production of natural, allergy-friendly BioRubber derived from the renewable, crop Guayule was honored with the 2013 AZBio Fast Lane Award from the Arizona Bioindustry Association
2012 AZBio Fast Lane Award Winner - Ulthera
Beauty and Growth – Ulthera, Inc Ulthera’s mission is to work with physicians to provide therapeutic ultrasound to improve the appearance and health of patients worldwide. The company is not only defined by its proprietary technology, but also its people. Ulthera’s team consists of experts in their respective fields who are aligned by the strength of the company’s mission and its leadership. Ulthera was founded in 2004 to leverage seven years of prior scientific research in therapeutic ultrasound for aesthetic and medical applications. In 2009, the Ulthera® System received FDA approval in the United States and is the first and only energy-based device to receive FDA clearance for a non-invasive aesthetic lift indication. The first application for Ultherapy® – the procedure enabled by the System – is a non-invasive treatment of the face to achieve a brow lift. Ulthera’s robust scientific foundation and relentless pursuit of superior clinical outcomes have resulted in the rapid global uptake of the Ulthera platform. As Ulthera continues to develop and provide more applications for its platform, the company also remains committed to bringing value to physicians and their patients. In 2006, Matt Likens was hired as President and CEO of Ulthera by founder and owner Michael Slayton, Ph. D, with the expectation of obtaining FDA approval for Ulthera’s product and service (known as Ultherapy) within three months. Less than two years into his tenure at Ulthera, Matt found himself navigating this venture capital backed start-up though the worst economic downtown since the Great Depression. The Company also found itself facing an increasing skeptical and less commercially friendly US Food and Drug Administration (FDA) regime. With both of these risks significantly threatening the Company’s viability, Matt decided to change the Company’s regulatory pathway and focus by obtaining CE Mark from the European Union prior to obtaining FDA clearance. If this bet paid off, Ulthera’s regulatory runway would be significantly reduced and the Company would be able to generate sales in the European market. These revenues would also allow the Company to lessen the need to obtain additional venture capital financing thus reducing additional dilution to the Company’s current shareholders. While risky, the core of this decision was based on the multinational experience Likens attained at Baxter and his general entrepreneurial nature. The bet ultimately paid off. Today, Ulthera is a global, growth-stage medical device company pioneering aesthetic and medical applications using its therapeutic ultrasound platform technology. More than 1,000 Ulthera Systems have been sold globally while treatments performed using the System have surpassed 100,000.